This article was originally published in The Gray Sheet
Cytyc extends purchase offer expiration date for Digene's outstanding shares to April 11 from March 28 after receiving formal request from FTC for additional information and documentary material concerning the proposed acquisition. Cytyc inked the $554 mil. deal in February (1"The Gray Sheet" Feb. 25, 2002, p. 3)...
You may also be interested in...
The payback on Cytyc's $554 mil. acquisition of Digene could get a quick boost from Digene's pending primary screening indication for DNA Pap for cervical cancer
Second read-out maintains 94% level of efficacy, with a very early signal that it could outperform Pfizer’s rival mRNA candidate in preventing severe cases.
The French major and Regeneron have racked up another indication for Dupixent with the blockbuster getting approval in Europe to treat children with severe eczema.